A Novel Liver X Receptor Agonist Establishes Species Differences in the Regulation of Cholesterol 7α-Hydroxylase (CYP7a)

John G. Menke(Merck & Co., Inc., Rahway, NJ, USA (United States)), Carl P. Sparrow(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jianhua Wang(Dalian Ocean University), Gaochao Zhou(Shenyang Pharmaceutical University), My‐Hanh Lam(Pfizer (United States)), Linda Kelly(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alex Elbrecht(Merck & Co., Inc., Rahway, NJ, USA (United States)), Samuel D. Wright, Karen L. MacNaul(Merck & Co., Inc., Rahway, NJ, USA (United States)), David E. Moller(Unknown), Nancy S. Hayes(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yu‐Sheng Chao(Merck & Co., Inc., Rahway, NJ, USA (United States)), Soumya P. Sahoo(Merck & Co., Inc., Rahway, NJ, USA (United States)), Joanne Baffic(Merck & Co., Inc., Rahway, NJ, USA (United States)), Azriel Schmidt(United States Military Academy), Patrick Xin(Merck & Co., Inc., Rahway, NJ, USA (United States))
Endocrinology
July 1, 2002
Cited by 76


Related Papers